Repronovo Appoints Mark Altmeyer as Chairman of The Board
20 Mar 2026 //
GLOBENEWSWIRE
ReproNovo Enrolls First US Patient in Ph 2 RPN-001 Trial
01 Jul 2025 //
GLOBENEWSWIRE
ReproNovo Raises $65M Series A to Advance Phase 2 Trials
21 May 2025 //
ACCESSWIRE

Market Place
Sourcing Support